Immunity Against SARS-CoV-2 (COVID-19) and Safety Following Evusheld (Long-acting Antibody) in Immunocompromised Children and Adolescents

Faculty of Medicine Siriraj Hospital, Mahidol University0 个研究点目标入组 70 人开始时间: 2023年4月6日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Males or females 5 - < 18 years of age and weights more than or equal 20 kg(s).
•2. Participants in a research with immune deficiency and symptoms were stable, classified as malignant or non-malignant.
•3. Participants or guardian of participant understand(s) Thai language through speaking, reading and writing
•4. Participants or guardian of participant be able
•to communicate through electronic tools such as Google form or line.
•5. Capable of attending all study visits according to the study schedule.
•6. Capable of informed assent/consent and provision of written informed consent before any study procedures

•1. Have history of severe drug or vaccine allergy (anaphylaxis)?
•2. Have history allergic to the components of the
•3. Participant has an infection or who has the
•history of COVID-19 infection within the last 90 days? or who has at higher risk of getting COVID-19
•4. Did not receive any vaccine COVID-19 within 12
•weeks before the enrollment?
•5. Have any symptoms of acute illness within 3 days
•before the enrollment?
•6. Be pregnant?

发起方